At present, the FDA has approved three monoclonal antibodies for the treatment of MM, including daratumumab (anti-CD38), elotuzumab (antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7)), approved in 2015, and isatuximab (anti-CD38), approved in 2020. This evidence concerns the gene CD38 and Miyoshi myopathy.